Pure Global AI
NCT06109558Not yet recruiting

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

A Prospective Clinical Research of Efficacy and Safety of LMV-12(HE003) Combined With Osimertini in the Treatment of Advanced Non-small Cell Lung Cancer That Has Previously Failed EGFR Inhibitor Therapy
Hunan Province Tumor HospitalClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
LMV-12(HE003) and Osimertinib
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Hunan Province Tumor Hospital
Location
Changsha, China
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Nov 30, 2024
Enrollment
20 participants
Primary outcome

ORR,PFS,DOR,DCR,OS

Summary

This is an open-label, single-arm, dose-escalation, multicenter phase I clinical trial. The
 primary endpoint of this study is to evaluated the safety, tolerability, pharmacokinetic
 profile and preliminary efficacy of HE003 in combination with osimertinib in patients with
 advanced solid tumors who have failed previous standard therapy.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06109558
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06109558 through Pure Global AI's free database. This phase not specified trial is sponsored by Hunan Province Tumor Hospital and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.